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Summary 
Regulation of expression of interleukin 7 (IL-7) mRNA is aberrant in the leukemic subset of 
cells of chronic lymphocytic leukemia (CLL) patients. The entire coding sequence for IL-7 as 
well as an alternatively spliced IL-7 mRNA are transcribed in these leukemic cells. No IL-7 mRNA 
expression is  detected in fresh peripheral blood  mononuclear cells  from normal individuals. 
Furthermore, the "normal" nonleukemic subsets  of cells isolated from the same CLL patients 
also do not express  IL-7 mRNA. The only subset of cells in which IL-7 mRNA is detected is 
the one that contains the leukemic cells themselves. The polymerase chain reaction was used 
to examine cytokine expression, and flow cytometry was used to purify the various subsets  of 
peripheral blood mononuclear cells examined in these studies, as well as to examine IL-7 receptor 
expression. A proportion of the cells from the CLL patients express receptors that are capable 
of binding IL-7, whereas T  cell-depleted normal cell preparations do not express receptors for 
IL-7 that are detectable with IL-7 fluorokines. The IL-7 receptor-bearing cells in CLL patients 
include a portion of leukemic cells and a fraction of the T cells, as well as some non-T, non-B 
cells. These findings suggest that IL-7 and IL-7 receptor expression in CLL may be relevant not 
only to growth regulation of the leukemic cells but to the immunological abnormalities that 
occur in the disease as well, possibly via the induction of inappropriate immune activity of IL-7 
receptor-bearing cells. 
C 
hronic  lymphocytic leukemia  (CLL) 1 is  a  relatively 
stable,  common form of leukemia, with >90%  of B 
cell CLL cases resulting from the leukemic transformation 
and clonal expansion of a single B lymphocyte within the 
CD5 + subset  (1-3).  CD5 + B cells account for 5-25%  of 
circulating and splenic B lymphocytes in normal adults, and 
may serve as the first line of immunological defense against 
microorganisms in infants, as these cells frequently produce 
IgM antibodies that are polyspecific (4-11).  CLL cells them- 
selves are relatively mature B cells but usually do not actively 
secrete Igs. They exist in a quasi-quiescent state,  with only 
m3% of the population in cell division. Patients with CLL 
often experience a suppression of immune responses and, in 
contradistinction, autoimmunity. An increased incidence of 
colon and skin cancers may be a reflection of depressed T 
cell immunity (12-16). The abnormal immune functions ob- 
served in CLL may be mediated by products of the B cell 
1  Abbreviation used in this paper: CLL, chronic lymphocytic  leukemia. 
malignancy and, furthermore, may be a determining factor 
in the chronic nature of the disease. 
A number of studies have suggested that growth factors 
and/or their receptors have a role in CLL. High concentra- 
tions of soluble IL2 receptors, for example, have been de- 
tected in the serum of CLL patients, and IL-1 production by 
CLL cells has been documented (17-23). Other studies have 
suggested a role for TNF in supporting the proliferation of 
CLL cells (24, 25). Another potential growth regulatory factor 
for CLL would be IL7 and/or IL-7 receptors. IL-7 is a stromal 
cell-derived growth factor for early lymphoid stem cells, in- 
cluding progenitor B and Pre-B cells, as well as for pre-T and 
cytotoxic cells (26-31). Our laboratory became interested in 
cytokine growth signals associated with leukemia cells when 
we found an IL-1 receptor-associated marker on CLL cells 
(32-34). We postulated that a cytokine(s) and its receptor(s) 
might contribute significantly both to leukemic transforma- 
tion  and  to the immune anomalies associated  with  CLL. 
Cytokines or cytokine receptors could also effect the chronic 
state of the leukemia by inducing nonleukemic immune cells 
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asked was whether endogenously produced cytokines and/or 
cytokine receptors might serve a role in the leukemic trans- 
formation of B cells. We approached the analysis of cytokine 
and cytokine receptor expression via the PCK (35)  and in- 
cluded  an  examination  of  the  expression  of  a  variety  of 
cytokines/cytokine receptors associated with B  cell growth 
and  differentiation.  Flow  cytometry  was  used  to  isolate 
mononuclear cell subsets, to examine expression of receptors 
for II:7, and then to phenotype I1:7 receptor-bearing cells. 
A portion of the data obtained is presented here and demon- 
strates that PBMC from CLL patients express I1:7 mKNA 
while  cells from normal blood  donors  do  not. 
Materials and Methods 
Cell Sources.  Peripheral venous blood from leukemic patients 
was obtained through the Hematology Service at Rush Presbyterian- 
St. Luke's Medical Center (Chicago, IL). Normal donor cells were 
from laboratory personnel or were purchased as buffy coats from 
units  of same-day donations  through  Lifesource (Chicago,  IL). 
Mononuclear cells were immediately isolated after a 1:1 dilution 
of the blood in 10 mM PBS, pH 7.2, by centrifugation on 5 ml 
per tube of a Hcoll-Na diatrizoate solution (Organon Teknika Corp., 
Durham, NC). The cells were removed from the interface, washed, 
counted, and frozen in aliquots of ~1-3  x  107 each. The cells re- 
covered upon  thawing  were generally from 75  to 95%  viable. 
Samples of the leukemic patients' cells were also phenotyped for 
cell surface markers by flow cytometry. A summary of relevant clin- 
ical information and surface phenotype expression on the individual 
patients reported here is presented in Table  1. 
Cell Surface Markers.  Directly labded mAbs to the cell surface 
markers, CD3, CD4, CDS, CD8, CD19, CD20, CD13, CD45, 
HLA-DR, as well as for r  or X light chains, were purchased from 
Becton Dickinson & Co. (Mountain View, CA). The mAbs were 
directly conjugated with either FITC, PE, or peridinal chlorophyll 
protein (PerCP). OKT3, used in T cell depletion experiments, was 
purchased  from Ortho  Diagnostics  (Raritan,  NJ).  The Fluoro- 
kines  TM, IL-7 conjugated with either biotin or with PE (IL-7PE), 
were purchased from R  & D  Systems (Minneapolis,  MN). 
Isolation of Cell Subsets.  Leukemic cells were incubated on ice 
for 30 min with PE-hbeled anti-CD5 (Leu-1) and with HTC-labeled 
anti-CD19 or CD20 mAbs, then washed thrice.  The cells were 
analyzed in a FACStar Plus |  (Becton Dickinson & Co.) flow cytom- 
eter, and the double-labeled  CD5 +,CD19 + or CD5 +,CD20 + cells, 
or,  in  some cases,  the  single-labeled CD19+,CD20 +  or  CD5 + 
cells,  or  the  double-negative non-T,  non-B,  CD5-,CD19-/20- 
cells, were isolated by sorting. The sorted cells were again analyzed 
by flow cytometry to confirm the degree of purity, then washed 
and solubilized in a 4.0-M solution of guanidinium isothiocyanate. 
Normal cells, which contain a substantially smaller proportion of 
CD5,CD20 double-positive cells, were enriched for B cells initially 
by removing the majority population of T cells with mAbs directed 
against CD3. Briefly, 3-10  x  107 normal donor cells were treated 
with 100 #1 of OKT3 for 30 rain on ice, washed, then incubated 
with goat anti-mouse IgG antibodies conjugated to iron filings 
(Collaborative Research Inc., Bedford, MA). The iron filings plus 
adhering T  cells were removed by three cycles of incubation on 
ice with a magnet. The T cell-depleted, B cell-enriched prepara- 
tions were then treated with the fluorochrome-conjugated anti- 
bodies as above,  analyzed,  and sorted by a FACStar Plus  |  flow 
cytometer into CD5+,CD20 § B cell suspensions  or CD5 § 
non-T, non-B cells, or, ahematively, CD20 +,CDS- B cells, and the 
CD5 + cells that include the CD5 +,CD20 + B cells. We discovered 
that time and temperature were the two most important variables 
that would determine mKNA "stability" and, thereby, detection 
by PCK. The cells, thus, were kept cool throughout the fraction- 
ation  procedure,  and  KNA  was isolated immediately after cell 
sorting. 
Isolation of RNA, cDNA Synthesis, and PCR.  Cell pellets were 
resuspended and dissolved  in 4.0 M  guanidinium isothiocyanate 
containing 25 mM sodium citrate, pH 7.0, 0.5% sarkosyl, and 1.0% 
2-ME, and layered onto a 5.7 M cushion of CsC1 (36). The KNA 
was pelleted in a rotor of an Optima ultracentrifuge  (TL100.2; 
Beckman Instrs. Inc., Fullerton,  CA) for 2 h  at 175,600  g. The 
supernatant was carefully removed, the KNA pellet dissolved  in 
water, and the RNA precipitated overnight at  -20~  in 0.3 M 
sodium acetate and 2.5 vol of cold 100% ethanol. The KNA was 
pelleted during 30 rain in a centrifuge (Eppendorf North America, 
Inc., Madison, WI), washed in 70% cold ethanol, and dried under 
vacuum. The KNA was then dissolved in 30 #1 sterile water, and 
10 #1 was used for cDNA synthesis.  Random priming of mKNA 
was with oligo(dT)t5 (Promega Corp., Madison,  WI). AMV re- 
verse transcriptase was used to synthesize the cDNA at 37~  for 
2 h in a final volume of 25 #1. In a later refinement of the cDNA 
Table  1.  Cell Surface Phenotypes of CLL Patients 
CLL patient no.  Sex  Age  WBC  Stage  Percent  ~  Percent  r  CD5  CD20  CD3 
yr 
2  M  42  29  2  2  97  99  77  2 
3  M  42  14  4  1  76  98  87  9 
4  M  41  59  2  95  6  97  94  4 
5  F  59  53  1  4  97  95  92  4 
10  F  80  13  0  10  67  84  60  24 
11  F  67  22  1  1  84  18  41  11 
16  F  52  14  75  6 
25  F  67  4  2  23  11  69  36  51 
956  Interleukin 7 mRNA Expression in Chronic Lymphocytic Leukemias synthesis technique, the incubation time was reduced to 15 min, 
with full ability to detect the respective PCR products. 1/~1 of 
cDNA was generally used as a template for amplification in the 
PCK. Higher concentrations ofcDNA (5, 10, or 20/~1) were used 
to confirm negative PCR reactions. Primers for selected  cytokines 
and cytokine receptors used in these studies, the expected size of 
the PCK products for each, and respective  restriction enzymes that 
would yield discernible-sized fragments are listed (Table 2). All 
primers reported here were purchased from Clontech Laboratories 
Inc. (Palo Alto, CA). Standard GeneAmp  TM PCR was performed 
with Taq DNA polymerase,  200 #M dNTPs, 0.4/~M forward and 
reverse primers, 3 mM MgClz, and H20 to a final  volume of 50 
/~1 in siliconized tubes. After 35 or 40 cycles  of PCR, 7/zl of each 
sample was subjected to separation by agarose gel electrophoresis, 
stained with ethidium bromide, analyzed,  and photographed. Proof 
of identity of the PCK product of the appropriate size was deter- 
mined by restriction enzyme digestion into fragments of known 
sizes (Table 2). The data presented  in this manuscript were obtained 
largely with I1-7 primers and include others only as necessary  for 
controls to demonstrate that an experiment was a technical  success. 
A more inclusive report with these as well as other primers will 
be published elsewhere. The primer set for the 11-2 receptors are 
for the p55, TAC, ce chain. 
Southern Hybridizations.  Clonal rearrangement of leukemic Ig 
genes was examined in Southern hybridizations with the Jh probe, 
C76R51 (37). DNA was isolated  from total PBMC and from subsets 
sorted by flow cytometry, then cut with the restriction enzyme 
EcoKI. The DNA samples were separated overnight in a 0.7% 
TAE-buffered agarose gel, transferred to a nylon membrane, and 
probed with 32P-labeled C76R51 (38). 
Results 
IL,7 raRNA Expression Was Detected by PCR in PBMC  from 
CLL Patients but Not from Normal Donor Cells.  Cytokine 
expression  was evaluated to determine whether a particular 
cytokine was consistently expressed in CLL patients' PBMC 
that was not expressed in normal individuals. Our data re- 
vealed  that II,7 was expressed  in ceils from 20 of 20 CLL 
Table  3.  IL-I~,  IL-2 Receptor, and IL-7 mRNA Expression in 
PBMC Isolated  from  CLL Patients and Normal Donors 
CLL donors  Normal donors 
IL-lfl  14/18  7/7 
IL-7  20/20  0/7 
IL-2R  16/18  5/7 
patients tested (Table 3).  The I1--7 PCR product migrated 
in agarose gel electrophoresis to the approximate size predicted 
for an mRNA-derived template (681 bp; Fig. 1, lane 2). Diges- 
tion of the II.-7 PCK product with the restriction enzyme 
PVUII revealed two fragments as expected (379 and 302 bp; 
Fig. 1, lane 3). To rule out contaminating DNA as the source 
of template, PCR analyses  were also performed with an equiva- 
lent amount of the RNA preparation. No II:7 product was 
evident in the absence of a cDNA template (Fig.  1, lane 4). 
The reverse and forward primers for Ib7 span  five introns 
of genomic sequence, therefore, a PCK product derived from 
genomic DNA would be substantially larger (i.e., several  kilo- 
bases). The data from these experiments revealed that mRNA 
for I1:7 indeed was expressed  in cells from CLL patients. 
No I1:7 mRNA was detected in cells obtained from normal 
individuals (0/7)  (Table 3).  Positive  PCR products,  either 
I1:1fl,  I1:2R, or both, demonstrated that the experiments 
were technical successes. One concern, however, was whether 
the difference in the ability to detect Ib7 mRNA was a reflec- 
tion of the large numbers of CD5 + leukemic B cells present 
in CLL patients or was undetected because  of the substan- 
tially smaller number of CD5 + B cells in normal individ- 
uals. Two approaches were used to resolve this issue. First, 
the minimal number of CLL cells required to detect I1:7 
mRNA was determined. While a faint band for I1:7  was 
detected at low numbers of CLL cells (5  x  10  s and 1  x 
Table  2.  Primer  Sets for PCR 
Cytokine  Sequence* forward/reverse  PCR product  Restriction  enzyme  Fragment size 
bv 
IL-loe  5'ATGGCCAAAGTTCCAGACATGTTTG 3'  816  HindilII  617,  190 
5'GGTTTTCCAGTATCTGAAAGTCAGT 3' 
IL-lfl  5'ATGGCAGAAGTACCTAAGCTCGC 3'  802  PVUII  591, 210 
5'ACACAAATTGCATGGTGAAGTCAGTT 3' 
IL-2R  5'GAATTTATCATTTCGTGGTGGGGCA 3'  398  NCOI  274, 123 
5'TCTTCTACTCTTCCTCTGTCTCCG 3' 
IL-6R  5'CATTGCCATTGTTCTGAGGTT 3'  251  HAEIII  142, 109 
5'AGTAGTCTGTATTGCTGATGTC 3' 
IL-7  5'ATGTTCCATGTTTCTTTTAGGTATATCT 3'  681  PVUII  379, 302 
5'TGCATTTCTCAAATGCCCTAATCCG 3' 
* From Clontech Laboratories, Inc. (Palo Alto, CA). 
957  Frishman  et al. Figure  1.  1I-7  PCR product from 
CLL patients' cells before and after 
restriction  enzyme digestion with 
PVUII. Lane 1,  123-bp ladder: lane 
2, I1-7 PCR product of cDNA tem- 
plate synthesized off RNA isolated 
from CLL patient's total peripheral 
mononuclear  cells; lane  3, after  PVUII 
digestion;  lane 4,  lack of a  PCR 
product from the RNA preparation 
as template  and the I1-7 set of  primers. 
The expected size of the 11-7 PCR 
product was 681 bp, while the PVUII 
fragments were 379 and 302 bp. No 
product was observed  with the RNA 
as template. 
10  6)  (Fig.  2,  lanes  4  and  7),  no IL-7 product  was  detected 
with high numbers of normal donor cells (107) (Fig. 2, lane 
11). "CD5 + ,CD20 + cell equivalents" were calculated based 
on dual marker studies of these donors. Whereas an IL-7 PCR 
product was readily detected with ,,~1,300 "CD5 § ,CD20 § 
CLL cell equivalents" and actually could be observed at 650 
"cell equivalents" (Fig. 2, lane 7), no Ib7 PCR product was 
evident at ,~2,050 "CD5 + ,CD20 + normal cell equivalents" 
(Fig. 2, lane II). IblB and IL2R PCR products were readily 
Figure  2.  Normal donor cells  do not yield an Ib7 PCIL  product. RNA 
was prepared from increasing numbers of CLL no. 10 and normal donor 
(LS no. 8) peripheral mononuclear cells. An I1-7 product was observed 
with the lowest number of CLL cells used in this experiment, 0.5  x  106 
(lanes 2-4). More intense bands were observed with higher numbers of 
CLL cells. Results from 106 cells are reported here (lanes 5-7). Cell equiva- 
lents were calculated  to determine the maximum number of cells that con- 
tributed template for the 7/~1 of PCR product loaded into the gel based 
upon a theoretical yield of 100%. This number was used to calculate the 
minimum number of normal donor cells required to start with an equiva- 
lent number of CD5 + B cells. Normal donor cells at 10  x  106 repre- 
sented greater than twice the minimum number of cell equivalents re- 
quired (lanes 9-11).  Lanes I and 8, 123-bp ladder; lanes 2-4, 0.5  x  106 
CLL cells, PCR products of primers for Ibl/8,  Ib6 receptor, and IL-7, 
respectively;  lanes 5-7,  106 CLL cells, PCR products of primers for IL-lfl, 
IL-6 receptor, and I1-7, respectively;  lanes 9-11, 10  x  106 normal donor 
cells, PCR products of primers for I1-1B, I1-2 receptor, and 11-7, respec- 
tively; lanes 12 and 13, 11-1fl PCR products from 106 and 0.5  x  10  6, 
respectively. 
detected with 107 normal ceils, while ILl3 was also readily 
detected with  106 as well as  5  x  10  s normal cells (Fig.  2, 
lanes 9,  10,  12,  and 13,  respectively). The IL-lfl as well as 
Ib6R primers  also served as positive controls for the CLL 
RNA and cDNA preparations (Fig. 2, lanes 1 and 5, as well 
as lanes 3  and 6,  respectively).  It was  apparent  from these 
studies that IL-7 mRNA was expressed in mononuclear cells 
isolated from CLL patients but not in an equivalent number 
of cells isolated from normal individuals.  In the second ap- 
proach to investigate IL-7 mRNA expression in normal cells, 
flow cytometry was  used to enrich for the normal CD5 +, 
CD20 +  B  cells.  No  detectable  expression  of IL-7 mRNA 
(data reported below,  see Fig.  5) was observed in the sorted 
normal  B  cells. 
The Subsets of  B Cells That Contain the Leukemic Cells Ex- 
pressed mRNA for IL 7 while the Nonleukemic  Subsets of the 
CLL Patients Did Not Express Detectable 11_:7 mRNA.  We 
sought to determine whether the leukemic cells themselves 
expressed IL-7 mRNA. Dual-color fluorescence and cell sorting 
were used to isolate cell subsets with antibodies directed against 
either of the pan-B  cell markers,  CD19 or CD20,  and  the 
B cell subset marker, CD5.  mAbs to CD20 were used with 
normal cells and  the initial three CLL patients  (nos.  1-3), 
while mAbs to CD19 were used more recently with the CLL 
cell preparations.  CD5 also serves as a pan-T cell marker. Ex- 
amination of T-depleted, B-enriched mononuclear cells from 
a normal donor revealed a density map profile of fluorescence 
expected from these two markers (Fig.  3 A).  The majority 
subset now consisted of single-positive CD20 + cells as seen 
in the upper left quadrant, while the second most prominent 
subpopulation  was  the double-negative,  non-T, non-B cells 
observed in the lower left quadrant,  and, a third, less preva- 
lent subpopulation  of residual CD5 +  T  cells was  observed 
in the lower right of the contour map (Fig. 3 A). The double- 
positive  CD5+,CD20 +  cells  were  hardly  discernible  as  a 
distinct subpopulation in the upper right quadrant.  In con- 
trast,  most  CLL patients  had  a  majority  subpopulation  of 
CD5+,CD19+/20 §  cells,  as  observed  in  the  upper  right 
quadrant  (Fig.  3  B).  The proportion  of T  cells,  CD5-  B 
cells, and non-T, non-B cells observed varied with each pa- 
tient.  The double-positive CD5 +,  CD19 +/20 + population 
in  five of the  CLL patients  ranged  from  25  to  93%  with 
a median of 71%.  The contrast between normal donor and 
the CD5 +  leukemic patients  as  observed in  Fig.  3,  A  and 
B, reflects the overwhelming contribution of the monoclonal 
leukemic population. 2 of 11 patients examined by dual-color 
analyses,  however, had relatively few double-positive cells, but 
instead had a CDS-,CD19 + majority B  cell subpopulation 
and evidently had the more rare form of CD5-  CLL (Fig. 
3  C).  Parameters  were  then  set  to  isolate  the  normal 
CD5 +,CD20 +  cells,  the  CLL  patients'  CD5 +,CD19 +  or 
CD5- ,CD19 + cells, as well as other selected subpopulations. 
Contour  maps  of the dual-labeled  mononuclear cells from 
the three respective types of individuals before and after cell 
sorting are presented:  normal (Fig. 4 A),  CD5 + CLL (Fig. 
4 B),  and CD5-  CLL (Fig. 4  C).  Each isolated subset was 
reexamined by flow cytometry and found to consist of >96% 
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ysis of peripheral mononuclear cell 
preparations from T  cell-depleted 
normal donor, from a CD5 + CLL 
patient,  and  from  a CD5-  CLL 
patient. Live acquisition data of 106 
events from analyses on a FACStar 
Plus  ~ C_~ ptt'~tions were stained 
with a fluorescein-conjugated  anti- 
CD5  and  a  PE-conjugated  anti- 
CD19 or CD20. (A) T cell-depleted 
normal donor cells, LS no.  1. (B) 
CD5 + CLL no. 4 cells. (C) CDS- 
CLL no.  16 cells. 
purified cells (Fig. 4, right).  The cells were then washed and 
processed for the isolation of RNA.  Complementary DNA 
was synthesized, and PCR assays were performed. The PCR 
data demonstrated that the B cell subsets that contained the 
respective leukemic population expressed IL-7 mRNA  (Table 
4  and  Fig.  5,  lanes 2  and 3,  respectively).  IL-7 mRNA  was 
expressed in CD5 + ,CD19 +/20 + cells of the CD5 + patient, 
whereas  Ib7  mRNA  was  detected  in  CD5-,CD19+/20 § 
cells  of  the  CD5-  patient.  Neither  the  normal  donor 
CD5 + ,CD20 §  nor the normal CD5-,CD20 + B cell subsets 
expressed detectable levels of II.-7 mRNA  (Table 4  and Fig. 
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Fractionation of cell subsets from a T cell-depleted normal 
donor, a CD5 + CLL patient, and a CD5- CLL patient. Contour maps 
were derived from an analysis of 10,000 cells before (left) and after (right) 
cell sorting. (A) T cell-depleted normal donor cells, LS no. 2. (B) CD5 + 
CLL no.  10 cells. (C) CD5-  CLL no.  11 cells. 
5, lanes 4 and 7, respectively). Normal CD5 § B cells, how- 
ever, did express IL-lfl, thereby demonstrating:  r  that the 
experiments were technically successful, and (b) t,,at the ex- 
pression of IL-lfl is a normal function of CD5 + B cells (Fig. 
5, lane 5).  The predominant  CD5-,CD20 + normal B  cells 
also express IL-1B but to a lesser degree (Fig. 5, lane 7). Equiva- 
lent levels of Ib6R PCR products were detected in both subsets 
of B  cells (Fig.  5, lanes 6  and 9).  Ib2R  expression was evi- 
dent in both B cell subpopulations (38a). These data demon- 
strate, therefore, that the synthesis and secretion of IL-1/~ by 
CLL cells most likely is unrelated to their leukemic transfor- 
mation. Expression of IIr  however, is unique to cells from 
the  CLL patients. 
Other cell subsets from the CLL patients were also exam- 
ined  for expression  of II.-7 mRNA:  T  cells,  as  defined by 
the surface expression of CD5 but the absence of CD19/20; 
non-T, non-B cells,  as defined by the lack of surface expres- 
sion  of both,  CD5  and  CD19/20;  conventional  B  cells,  as 
defined by the expression of CD19 but the absence of CD5; 
and  the total pool of CDS-  cells,  which  contained  a mix- 
ture of conventional B cells and non-B, non-T cells. The only 
Table  4.  Cytokine  and Cytokine  Receptor Expression in 
Leukemic  Cell Subsets 
Patients  IL-lc~  IL-IB  IL-2R  IL-7 
CD5 +,CD20+/19 § 
CLL  1 
CLL  2 
CLL  3 
CLL  10 
CLL 4 
CDS-,CD20 +/19 + 
CLL  16 
CLL  11 
+  +  + 
+  + 
-  + 
+  +  + 
+  +  + 
-  + 
+  +  + 
CLL nos. 1-3 were fractionated by flow cytometry sorting  using the 
mAb Leu-16 directed against the B cell marker CD20.  CLL nos. 10, 
4, 11, and 16 were fractionated similarly using the mAb Leu-12 directed 
against the B cell marker CD19. 
959  Frishman et al. Figure  5.  PCR products of mRNA obtained  from purified  B cell subsets. 
Lane 1,123-bp ladder; lane 2, CD5+,CD19 + CLL no. 4 cells with IL-7 
primers; lane 3, CD5- ,CD19  + CLL no. 11 cells with IL-7 primers; lanes 
4-6, CD5 § ,CD20 + normal LS no. 8 B cells with primers for I1:7 (lane 
4), I1:1/~ (lane 5), and Ib6 receptor (lane 6); lanes 7-9, CDS-CD20 + 
normal LS no. 8 B cells with primers for I1:7 (lane 7), IblB (lane 8), 
and Ib6 receptor (lane 9). 
cell fractions  that  yielded  mKNA-derived  IL-7 PCR  prod- 
ucts were the leukemic subsets from the CLL donors  (Fig. 
6,  lanes 2  and 6).  Neither  the nonleukemic  CD5-,CD19 + 
B  cells  isolated  from  the  same CD5 +  leukemic  individual 
(lane 4) nor their CD5 + ,CD19-  T  cells (lane 3) yielded an 
IL-7 PCR  product.  Positive control primers for IL-13 with 
the CD5--sorted fraction yielded a major band at 802 (lane 
5), demonstrating  that sufficient cDNA was available. Like- 
wise,  in the CD5-  CLL patient,  neither the CD5 § 
T  cells (lane 7) nor the collective CD5- ,CD19-  non-T, non- 
B  cells yielded an IL-7 PCR  product  (lane 9), but  each ex- 
pressed IL-6R PCR products  (Fig.  6,  lanes  8  and  10).  The 
yield of PCR products obtained with positive control primers 
tested  in  the  IL-7--sorted fractions,  of either  the  CLL  pa- 
tients  or  the  normal  donors,  were  of levels comparable  to 
those obtained with these primers in the IL-7 §  frac- 
tions.  Furthermore,  the IL-7-  cell fractions remained nega- 
tive after increasing the volume of template in the PCK mix- 
ture by as much  as 20-fold.  The absence of detectable  Ib7 
PCR product,  therefore, was most likely due to the absence 
of or  substantially  diminished  levels  of IL-7 mKNA. 
Proof of Clonality of CLL Patients' Cells  Using an Ig Heavy 
Chain  Marker, Jh  Probe.  Southern  hybridizations  revealed 
that  leukemic  cells purified  by flow cytometry cell  sorting 
exhibited clonality in that no germline genes and only rear- 
ranged  genes were  detected  in  the  sorted  fractions  (Fig.  7, 
lane  7  [unsorted];  lane 8  [sorted]).  Unrearranged  germline 
genes  were  strongly  detected  at  18  kb with  normal donor 
cells  (Fig.  7,  lane 2),  and  only moderately  detected  in  un- 
sorted cells of five different leukemic patients  (Fig.  7,  lanes 
3-7). In fact, in patient CLL no. 2's total PBMC sample, few 
normal cells were detected as evidenced by the weakness of 
the germline band and the preponderance of the clonally rear- 
ranged band (Fig. 7, lane 4). Analysis of flow cytometry-sorted 
Figure  6.  Only the leukemic subsets of B cells have mRNA for I1:7. 
Peripheral mononuclear CLL patients' cells were tagged with antibodies 
to the markers of CD5 and CD19 and fractionated into T and B cell subsets 
as well as non-T, non-B cells. Lane I, 123-bp ladder; lanes 2-5, PCK prod- 
ucts of flow cytometry-sorted cells from CD5 + patient, CLL no. 4. Lanes 
2-4, IL-7  PCR primers with CD5* B cells (lane 2), with CD5 +  ,CD19 - 
T cells (lane 3), and with all CD5- cells (lane 4). The latter sort should 
include the CD5- majority class of B cells as well as non-T non-B cells. 
Primers for IL-1/~  served  as their positive  control (lane 5). Lanes  6-I0, PCR 
products of flow cytometry sorted cells from CD5- patient, CLL no. 11; 
lane 6, cDNA-derived I1:7 PCR products from CD19 +  ,CDS- cells; lane 
7,  II~7 primers with CD5 +,CD19--sorted  T  cells, with 1I.-6 receptor 
primers serving as the positive control (lane 8); lanes 9 and 10, Ib7 and 
II:6 receptor primers, respectively  with CD5- ,CD19-  non-T, non-B cells. 
Figure  7.  Southern hybridizations demonstrate clonality of CLL cells. 
EcoRl-digested DNA was subjected to etectrophoresis and probed with 
32p.labele  d jh  probe. DNA was isolated from total  PBMC  of normal 
donor LS no. 7 (lane 2) and of patients CLL no. 23 (lane 3), CLL no. 
2 (lane 4), CLL no. 10 (lane 5), CLL no. 11 (lane 6), and CLL no. 4 (lane 
7), and from flow cytometry-sorted double-positive CDS,CD19 B cells 
from CLL no. 4 (lane 8). HindilII-digested X markers at 23.1 and 9.42 
kb are visible in lane 1. 
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line gene band in the CD5 +,CD19 § leukemic subset (Fig. 
7,  lane 8).  These data are consistent with previous  studies 
demonstrating clonal Ig gene rearrangements in neoplastic 
B cells (39-41). 
IL-7 Receptors Are Expressed on CeUs  from CLL Patients.  If 
II,7 serves a function in CLL, then one would expect that 
CLL patients' cells would express receptors for I1,7. Fluores- 
cent dye-tagged cytokines were used with flow cytometry 
to evaluate I1,7 binding and to characterize the cells that ex- 
pressed 11,7 receptors.  Positive binding of I1,7 was observed 
with cells from four of four CLL patients examined. The 
percentage  of total cells  that  stained  specifically  for  I1,7 
receptors varied between the patients from 1.1 to 53.4%. Each 
patient also had a variable percentage of the leukemic subset 
of B cells ranging from 20 to 96%. The percentage of specific 
I1,7 receptor-bearing cells in a given patient, however, was 
reproducible with an average deviation from the mean in CLL 
no. 2 of 2.67% in three replicate binding studies. The binding 
of biotinylated I1,7 to cells from two patients (CLL nos.  2 
and 5) but not to T-depleted normal donor cells (normal con- 
trol)  is depicted in Fig.  8.  CLL cells  incubated with the 
Streptavidin-PE (Avidin-PE) reagent without biotinylated IL-7 
served as the control for nonspecific reagent binding, and their 
fluorescence  curve  was  superimposable  over  the  normal 
T-depleted donor curve, demonstrating no evidence of  binding. 
The specificity  of I1,7  binding was evaluated  with recom- 
binant, unlabeled I1,7 incubated at a 100-fold greater molar 
concentration than I1,7-PE. An inhibition of I1,7-PE binding 
demonstrated the specificity of I1,7 binding to its receptors 
(Fig.  9 B). Approximately 53%  of this CLL patient's cells 
specifically bound I1,7-PE  (Fig. 9 C). Ib7 receptor-positive 
cells were surface phenotyped using anti-CD5 conjugated with 
I~ TO~,I"  M.~I  tt  TO~II=  t4,07 
".  !-"  ,,e 
I,,  ....  ~  ......  it,  ~  il 
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Figure  9.  Specificity  of IL-7  binding to CLL cells. (A) CLL no. 2 cells 
were labeled  with PE-conjugated  II,7. (B) A second sample of cells was 
preincubated  with 100-fold  molar  excess  of  unlabeled  purified  human  rlL-7 
before addition  of the PE-conjugated  Ib7. (C) A and B were  overlaid  and 
the specific  IL-7  receptor-bearing  cells in the white area under the curve 
were further analyzed  for expression of CD5 and CD20. 
FITC and anti-CD20 conjugated with PerCP. Three distinct 
subpopulations of 11,7 receptor-bearing cells were identi- 
fied.  The majority of the II.,7 receptor-positive cells were 
CD5-,CD20-  non-T, non-B cells. The CD5 + ,CD20 + leu- 
kemic  subset  comprised  approximately  half  of  the  I1,7 
receptor-positive cells, while CD5 + T  cells accounted for 
the remainder. Virtually no conventional CDS-,CD20 + B 
cells were I1,7 receptor positive. These studies revealed, there- 
fore, that while a proportion of the leukemic CD5 +  ,CD20 § 
subset of B cells expressed  detectable I1,7  receptors,  other 
subsets  in the patients' peripheral blood, including T  cells 
and non-T, non-B cells,  also expressed  IL-7 receptors. 
Discussion 
We have demonstrated that mRNA for the cytokine I1,7 
is expressed in cells from the leukemic subset of PBMC of 
patients with CLL. Normal B cells do not make detectable 
quantities of 11,7 mRNA. I1,7  serves as a progenitor lym- 
phoid cell growth factor normally produced by stromal cells; 
thus,  one possible  role of I1,7  in CLL may be to serve as 
an autocrine or paracrine growth signal for the proliferating 
subset  of B-CLL cells. Recent studies have suggested that 
I1,-7 can trigger proliferation in a variety of leukemic cells, 
Figure  8.  Flow cytometry  analysis of PE-streptavidin-biotin-conju- 
gated I1:7 bound to cells from two CLL patients, CLL no. 2 (black 
lines) and CLL no.  5 (gray lines), but not to normal T-depleted PBL 
(filled area). CLL cells incubated  with PE-streptavidin  but without bio- 
tinylated IL-7 are indicated as the hatched lines over the solid peak. 
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Table  5.  Cytokine  and Cytokine  Receptor Expression in 
CD5 +,CD20 + Normal  Cells 
Normals  IL-lcr  IL-1B  IL-2R  IL-7 
LS 2  -  +  + 
LS 7  -  +  + 
LS 8  +  + including CLL (42-45).  Most CLL cells,  however, are not 
proliferating, but accumulating, as rather mature B cells. IL- 
7, apparently, does not trigger proliferation in such mature 
B cells (46). Another possible role for IL-7 in CLL may be 
to serve as as a differentiation  signal to push the leukemic 
cells into this mature stage of nonproliferating B cells. A third, 
alternative hypothesis for the function of IL-7 in CLL is sug- 
gested by the fact that ILo7 binding was detected in a variety 
of cells from CLL patients, including T cells and non-T, non- 
B cells, as well as a portion of the leukemic B cells. A recent 
publication  suggested that  four of six CLL patients'  cells 
specifically  bound radiolabeled Ib7,  however, these studies 
did  not  reveal  the proportion  of CLL cells  or other  sub- 
sets that  may also express  Ib7  receptors  (42).  It  has  also 
been shown that IL-7 serves as a signal for the induction of 
cytotoxic T and NK cells (47-50). These studies suggest that 
IL-7 can serve as a potent inducer of antitumor cytotoxic cells. 
Tumor  cell-derived  IL-7 in  CLL could be triggering  IL-7 
receptors on nonleukemic cells and inducing such cell-mediated 
antitumor immunity, thereby resulting in the diminution of 
the disease  with  a prolongation  of the leukemic course. 
The fact that IL-7 expression was only detected in cells ob- 
tained from leukemic patients and not from normal donors 
suggests that II.-7 mRNA expression may be related to the 
leukemic transformation of these B cells (Table 3). Enriched 
normal  CD5+,CD20 +  B  cells  gave  no  evidence  for  IL-7 
expression,  but,  IL-2 receptor  expression  was  readily  de- 
tected  (Table  5).  The  normal  majority  B  cell  subset, 
CDS-,CD20 + , also expressed IL2 receptor but did not ex- 
press IL-7 (Fig.  5, lanes 2 and 3). It had been suggested that 
Ibl~ expression by CLL cells was related to their leukemic 
transformation (18-20). Our PCR data with normal B cells 
refute that hypothesis and indicate that IL-1B expression occurs 
as a natural event in B cells (Fig. 5, lane 5). The most com- 
pelling  evidence,  however,  that  II.-7 mRNA  expression is 
related  to  leukemic  transformation  stems  from  our  stud- 
ies with fractionated cells from CD5 § vs.  CD5-  CLL pa- 
tients  (Fig.  6).  In  the  CD5-  CLL patient,  an  Ib7  PCR 
product  was readily  detected  in  the  leukemic  cell  subset, 
CDS-,CD19 + (Fig.  6, lane 6). Yet,  in the CD5 + patient, 
an  I1.-7 PCR product  was not  detected in  the  same non- 
leukemic "normal  subset," CD5-,CD19 + (Fig.  6, lane 4), 
but,  again,  was  detected  in  the  leukemic  cell  subset, 
CD5 § ,CD19 + (Fig.  6, lane 2). These data strongly support 
the suggestion that the expression of ILo7 may be associated 
with  the leukemic transformation  of B cells. 
Our  findings  with  II.-7  differ  from  murine  lymphoma 
studies in that all human patients tested to date yield positive 
IL-7 PCR products with reverse-transcribed total RNA pre- 
pared from their cells (Table 3), while no II.-7 PCR product 
was detected in the mouse cells (51).  The reasons for these 
differences are unclear.  The primer  sets used in each study 
were quite different. The Ib7 primer sets used in our studies 
spanned six exons, with the 5' end of the PCR product be- 
ginning at the ATG initiation codon for the first amino acid 
of the signal sequence and ending subsequent to the coding 
sequence in the 3' noncoding region (52).  The 681-bp IL-7 
PCR product, therefore, contained the entire coding sequence 
for the IL-7 precursor protein.  The primer set for Ib7 used 
in the murine lymphoma study began and ended in the 3' 
noncoding region of the cDNA sequence. Perhaps the differ- 
ences in the primer  sets used in the two studies could ac- 
count for the dissimilar results observed, or perhaps stability 
problems for the IL-7 mRNAs occurred with the murine lym- 
phoma cells. 
In the Ib7 PCR products from CLL cells, a second, smaller, 
minor band was generally also evident at  "~550 bp, as ob- 
served in Figs.  1, 2,  5, and 6.  This second band represents 
a PCR product derived from an alternatively spliced cDNA. 
The isolation of the original cDNA clones for human IL-7 
revealed a deletion in one of the cDNA clones that was found 
to be due to alternative splicing (27). The alternative tran- 
script lacked the entire exon 4, which encodes 44 amino acids, 
thereby reducing the transcript size by 132 nucleotides. This 
size reduction corresponds precisely with the size of the second 
IL-7 PCR product band observed in our gels.  The PVUII 
restriction site of this alternatively spliced II.,7 transcript re- 
mains intact (27, 52). Upon PVUII digestion of our IL-7 PCR 
products, both the major and minor bands virtually disap- 
peared and only the two expected digestion product bands 
were obtained, as observed in Fig.  1. One of the restriction 
products of the alternatively spliced, minor band is identical 
with  the 302-bp band of the major IL-7 band's restriction 
product and should merge with it,  thereby appearing  as a 
more dense band than that of the larger 379-bp band, as ob- 
served in Fig. 1, lane 3. The second PVUII digestion product 
of the minor IL-7 PCR product should be '~247-bp and does 
not appear as a distinct third band in the figures presented 
here, but a diffuse band at the second marker band (246 bp) 
has been observed in gels where the undigested sample demon- 
strates a more dense alternate  spliced product. The significance 
of the alternatively spliced transcript remains unknown. Our 
ability to detect both the entire intact coding sequence for 
IL-7 and an alternative  spliced transcript that had been defined 
through molecular cloning lends further credence to our con- 
clusions that CLL cells transcribe ILo7 mRNA. The regula- 
tion of expression of Ib7 in CLL as well as a determination 
of its function in the disease  state remain as questions that 
need to be answered and are major areas of experimentation 
in our laboratory. 
Our data suggest that within a given patient only a propor- 
tion of the CLL cells express Ib7 receptors and that other 
peripheral  mononuclear cells, including some T cells and some 
non-T,  non-B cells,  also express IL-7 receptors. As has been 
the case for many of the cytokines, IL-7 has now been shown 
to have effects on a broader variety of cells than initially de- 
scribed, hence, IL-7 could also be effecting the T cell defects 
observed in CLL patients.  Besides the possible role of I1.-7 
in autocrine signaling of CLL growth and/or differentiation, 
it is also possible that  IL-7 may directly trigger the disease- 
associated immunological  aberrations  in CLL. 
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